Biotech stocks have always been high-risk and high-reward, with the futures and fortunes of companies often decided with a single successful drug trial or Federal Drug Administration (FDA) approval. The right company can yield extravagant returns for the lucky or prudent investor. However, choosing the wrong ones can lead to losses just as significant as the potential wins. Therefore, due diligence is important. A company announcing that it is developing a cure for cancer, MS, Huntington’s, or HIV is not en ...